Interview With Stephen Murphy

MindMed’s Financial Results & Business Update for Q2 2021 are out!
In this episode, we’ll discuss MindMed, ( MMED: NEO), (MNMD: NASDAQ), (MMQ: FRA), who recently announced their Q2 financials and gave a business update.
This was an important, transitional quarter for the company for several reasons.

First, and perhaps most significantly, during Q2, co-founder JR Rahn stepped down as CEO, being replaced by Robert Barrow, who was previously Chief Development Officer.

Second, in terms of progress in the mission to heal mental health, MindMed made several strides in this quarter, which we’ll discuss today.

Pertinent links:

MindMed’s CEO Jr Rahn Steps Down:
https://thepsychedelicinvestor.com/2021/06/09/mindmed-announces-chief-executive-officer-transition/

Project Angie Update:
https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/

MindMed’s Collaboration with NextStage Therapeutics:
https://mindmed.co/news/press-release/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/

MindMed’s Pharmacogenetic Study:
https://thepsychedelicinvestor.com/2021/05/26/mindmed-and-liechti-lab-in-basel-switzerland-publish-first-pharmacogenetic-data-on-lsd-to-help-guide-personalized-dosing/

MMED’s Q2 Financial Results & Business Update:
https://thepsychedelicinvestor.com/2021/08/13/mindmed-announces-2021-q2-financial-results-cash-balance-of-157-usd-million-195-cad-million-to-execute-on-diverse-clinical-pipeline/

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MindMedStock #MNMD

What’s up psychedelic stocks investors?!? Today marked atai Life Science’s (Nasdaq: atai) first-ever conference call, for Quarter 2, 2021. In the conference call, atai Life Sciences gave updates on their varying projects, ranging from attempting to treat depression, to cognitive impairment associated with schizophrenia. They also give insights on atai’s digital medicines division and answer investor’s questions at the end of the call.

This Peter Thiel-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 10+ different projects under their belt, atai is one of the most exciting companies to keep an eye on in the industry.

This conference call can help investors answer the questions: is atai stock a good investment? Will atai go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Check out our website: thepsychedelicinvestor.com

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

#atai #ataiLifeSciences #PsychedelicStocks

Hello back Psychedelic Investors! In this video we are going to be entering the Speculation Zone to discuss the implications of several of MindMed’s most recent moves. Aka, we shall be Speculating on The Future of MindMed [Big News for MMED/MMEDF STOCK].

Timestamps:
0:00 – Intro
2:52 – Speculating on LSD Trials
7:44 – MindMed’s Partnership Meaning
13:45 – Nasdaq Uplisting

This is actually the second video being released today. Earlier we posted a video detailing the three most recent press releases distributed by MindMed, where we explained what each move meant. If you haven’t seen that episode yet and want to get a detailed explanation of each Press Release before watching this video speculating on that information, you should probably do that first!

Well actually, MindMed has since released another press release since the first video was filmed, on the commencement of their LSD Neutraliser phase 1 clinical trial.
In our Video on MindMed’s Latest News, we discussed:

1. How MindMed has started a phase 1 clinical trial studying the effects of mixing LSD and MDMA;
2. We examined MindMed’s changes in Leadership, where JR Rahn became the sole CEO, and a gentleman by the name of Dr. Glick left the board;
3. We also talked about MindMed’s new partnership with a company called MindShift Compounds AG, which is developing novel compounds owned exclusively by MMED.

In this video, we discuss/SPECULATE on all of MindMed’s latest changes and how some of them could potentially influence the MMED/MMEDF stock’s uplisting on NASDAQ.

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video by Pressmaster from Pexels

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMEDF #MindmedStock